SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT06864013 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 116 participants, started 2025-01-06 and due to reach its primary completion in 2029-12-31. Interventions recorded: Experimental; Control. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Complete Response; Clinical Complete Response; Pathologic Complete Response. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.